Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors
First Claim
Patent Images
1. A method of potentiating a CD8+ response to human immunodeficiency virus-1 (HIV-1) epitopes in a human comprising:
- administering an expression vector encoding HIV-1 Gag, Pol, Pro, Tat, Nef, Rev, Vif, Vpr or Env antigens; and
administering a recombinant ALVAC pox virus encoding the same antigens encoded by the expression vector;
wherein the expression vector and the recombinant pox virus enter the cells of the humanand intracellularly produce HIV peptides that are presented on the cell'"'"'s MHC class I molecules in an amount sufficient to stimulate a CD8+ response, and further, wherein administration of the combination of the expression vector and the recombinant pox virus potentiates the immune response compared to administration of either the expression vector or the recombinant pox virus by itself.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to improved methods of inducing an immune response for the prevention or treatment of HIV-1 infection by using a nucleic acid vaccine in conjunction with a recombinant viral vaccine, e.g., a poxvirus vaccine, to potentiate and broaden the immune response. The present invention further provides a particularly effective vaccine regimen comprising a DNA vaccine used in combination with a poxvirus virus, especially NYVAC or ALVAC.
-
Citations
14 Claims
-
1. A method of potentiating a CD8+ response to human immunodeficiency virus-1 (HIV-1) epitopes in a human comprising:
-
administering an expression vector encoding HIV-1 Gag, Pol, Pro, Tat, Nef, Rev, Vif, Vpr or Env antigens; and administering a recombinant ALVAC pox virus encoding the same antigens encoded by the expression vector; wherein the expression vector and the recombinant pox virus enter the cells of the human and intracellularly produce HIV peptides that are presented on the cell'"'"'s MHC class I molecules in an amount sufficient to stimulate a CD8+ response, and further, wherein administration of the combination of the expression vector and the recombinant pox virus potentiates the immune response compared to administration of either the expression vector or the recombinant pox virus by itself. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of reducing viral load in a mammal that is infected with an immunodeficiency virus, comprising:
-
administering to the mammal an expression vector that expresses encoded immunodeficiency virus Gag, Pol and Env antigens; and later administering to the mammal a recombinant ALVAC pox virus encoding said antigens; wherein the expression vector and the recombinant pox virus enter the cells of the mammal and intracellularly produce said antigens, and wherein administration of the combination of the expression vector and the recombinant pox virus reduces the viral load more than administration of either the expression vector or the recombinant pox virus by itself.
-
Specification